Your browser doesn't support javascript.
loading
New Perspectives in Neuroprotection for Ischemic Stroke.
Pérez-Mato, María; López-Arias, Esteban; Bugallo-Casal, Ana; Correa-Paz, Clara; Arias, Susana; Rodríguez-Yáñez, Manuel; Santamaría-Cadavid, María; Campos, Francisco.
Afiliación
  • Pérez-Mato M; Translational Stroke Laboratory Group (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
  • López-Arias E; Translational Stroke Laboratory Group (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
  • Bugallo-Casal A; Translational Stroke Laboratory Group (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
  • Correa-Paz C; Translational Stroke Laboratory Group (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
  • Arias S; Stroke Unit, Department of Neurology, Hospital Clínico Universitario, 15706 Santiago de Compostela, Spain.
  • Rodríguez-Yáñez M; Stroke Unit, Department of Neurology, Hospital Clínico Universitario, 15706 Santiago de Compostela, Spain.
  • Santamaría-Cadavid M; Stroke Unit, Department of Neurology, Hospital Clínico Universitario, 15706 Santiago de Compostela, Spain.
  • Campos F; Translational Stroke Laboratory Group (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain; Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain. Electronic address: francisc
Neuroscience ; 550: 30-42, 2024 Jul 09.
Article en En | MEDLINE | ID: mdl-38387732
ABSTRACT
The constant failure of new neuroprotective therapies for ischemic stroke has partially halted the search for new therapies in recent years, mainly because of the high investment risk required to develop a new treatment for a complex pathology, such as stroke, with a narrow intervention window and associated comorbidities. However, owing to recent progress in understanding the stroke pathophysiology, improvement in patient care in stroke units, development of new imaging techniques, search for new biomarkers for early diagnosis, and increasingly widespread use of mechanical recanalization therapies, new opportunities have opened for the study of neuroprotection. This review summarizes the main protective agents currently in use, some of which are already in the clinical evaluation phase. It also includes an analysis of how recanalization therapies, new imaging techniques, and biomarkers have improved their efficacy.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Neuroprotectores / Neuroprotección / Accidente Cerebrovascular Isquémico Límite: Animals / Humans Idioma: En Revista: Neuroscience Año: 2024 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Neuroprotectores / Neuroprotección / Accidente Cerebrovascular Isquémico Límite: Animals / Humans Idioma: En Revista: Neuroscience Año: 2024 Tipo del documento: Article País de afiliación: España
...